Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 384 of 5804
-
New hope for hard-to-treat cancers: targeted combo therapy enters trials
Disease control Recruiting nowThis is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To evaluate the safety/tolerability and pharmacokinetic (P…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New heart valve mimics nature to improve blood flow in major trial
Disease control Recruiting nowProspective, randomized, controlled, multicenter, international study. Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'A…
Phase: NA • Sponsor: Anteris Technologies Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Promising drug for rare balance disorder enters final testing phase
Disease control Recruiting nowSpinocerebellar ataxias 27B (SCA27B) is caused by an expansion of ≥ 250 GAA triplets in the FGF14 gene and accounts for 15% of cerebellar ataxias (around 500 patients in France). It is a late-onset form often presenting paroxysmal episodes of ataxia and/or diplopia. The disease p…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope: Chemo-Free cocktail targets advanced colorectal cancer
Disease control Recruiting nowColorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard first-line treatment for advanced pMMR colorectal cance…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug aims to cut COPD attacks in patients with specific inflammation
Disease control Recruiting nowDepemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate t…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New stem cell combo could boost survival in blood cancer patients
Disease control Recruiting nowThis study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (hapl…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Brain gene therapy targets Parkinson's at its source
Disease control Recruiting nowParkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary …
Phase: PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:11 UTC
-
New hope for Crohn's scarring: risankizumab vs ustekinumab in major trial
Disease control Not yet recruitingThis study, titled "IL-23 Inhibitor Ustekinumab for the Treatment of Fibrotic Crohn's Disease: A Prospective, Open-Label, Randomized Controlled Study," is conducted by researchers from the First Affiliated Hospital of Wenzhou Medical University. The primary aim of this research i…
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 26, 2026 18:29 UTC
-
Heart-Safe breast cancer treatment shows promise in new trial
Disease control Recruiting nowThis is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due t…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could help control PKU – phase 3 trial now recruiting
Disease control Recruiting nowThe goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignme…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Heart surgery showdown: could a simple gas beat standard anesthesia?
Disease control Recruiting nowTo investigate whether the inhaled anesthetic desflurane, compared with propofol, exerts cardioprotective effects and reduces the incidence of severe postoperative major cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery.
Phase: PHASE3 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for advanced colorectal cancer: drug cocktail shows promise
Disease control Recruiting nowThe aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could 40 hours on your belly save more lives from lung failure?
Disease control Recruiting nowAcute respiratory distress syndrome (ARDS) is an acutely induced respiratory failure characterised by the appearance of bilateral alveolar opacities on imaging and hypoxemia(1). Among strategies that have proved beneficial in terms of patient outcome, prone position (PP) is one a…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Lifestyle makeover may boost breast cancer treatment success
Disease control Recruiting nowThe purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery. Pathologic complete (pCR) response means that no cancer…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New blood test could spot breast cancer early, saving lives
Diagnosis Recruiting nowCancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagn…
Sponsor: Oncoliq US Inc • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New immune combo targets hard-to-treat nose and throat cancer
Disease control Recruiting nowThis study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC). It is expected to investigate a novel therapeutic regimen with improved effic…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastas…
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Implantable stimulator aims to stop blood pressure swings in spinal cord injury
Disease control Recruiting nowEmpower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (\>1 year after SCI). T…
Phase: NA • Sponsor: ONWARD Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could Lab-Grown cells free diabetics from insulin shots?
Disease control ENROLLING_BY_INVITATIONThis study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in patients with type 1 diabetes mellitus (T1DM) or pancre…
Phase: EARLY_PHASE1 • Sponsor: Celregen Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New sedative could help preterm babies breathe on their own faster
Disease control Recruiting nowVery preterm neonates (born before 32 weeks' gestation) often require invasive mechanical ventilation (IMV) to manage respiratory insufficiency. In France, around 8,250 infants are born annually at \<32 weeks, with an estimated 5,000 needing IMV. Although non-invasive support suc…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC